Canaccord Genuity Raises PT and Estimates on Edwards Lifesciences (EW); Preview of Cohort A Panel
Tweet
Share
E-mailGet Alerts EW Hot Sheet
Price: $89.83 --0%
Rating Summary:
31 Buy, 14 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 25
Rating Summary:
31 Buy, 14 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 25
Join SI Premium – FREE
Canaccord Genuity maintains a 'Buy' on Edwards Lifesciences (NYSE: EW) price target of $103.00 (from $93.00).
Analyst, Jason R. Mills, said, "We expect FDA panel briefing documents for Cohort A to be posted this Monday, ahead of the Circulatory Devices panel Wednesday. We think two-year Cohort A results convincingly demonstrated that TAVI is non-inferior to SAVR in high-risk patients with severe symptomatic aortic stenosis. While we envision a typical “roller coaster” meeting, as panelists contemplate safety data and assess new data that emerged in two-year results, we would be buyers of EW heading into the Panel as we expect a favorable vote, which we do not think is fully contemplated in the stock."
For an analyst ratings summary and ratings history on Edwards Lifesciences click here. For more ratings news on Edwards Lifesciences click here.
Shares of Edwards Lifesciences closed at $86.34 yesterday.
Analyst, Jason R. Mills, said, "We expect FDA panel briefing documents for Cohort A to be posted this Monday, ahead of the Circulatory Devices panel Wednesday. We think two-year Cohort A results convincingly demonstrated that TAVI is non-inferior to SAVR in high-risk patients with severe symptomatic aortic stenosis. While we envision a typical “roller coaster” meeting, as panelists contemplate safety data and assess new data that emerged in two-year results, we would be buyers of EW heading into the Panel as we expect a favorable vote, which we do not think is fully contemplated in the stock."
For an analyst ratings summary and ratings history on Edwards Lifesciences click here. For more ratings news on Edwards Lifesciences click here.
Shares of Edwards Lifesciences closed at $86.34 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lowe's (LOW) PT Lowered to $275 at Guggenheim
- Advance Auto Parts (AAP) PT Lowered to $47 at UBS as Demand Environment Remains Tough
- Ross Stores, Inc. (ROST) PT Raised to $239 at UBS on Q2 Earnings Beat
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
